Hepatitis C and Amiodarone: Picking a DAA Regimen Around a Cardiac Drug That Can't Be Touched
A single patient, hepatitis C positive and stable on amiodarone for atrial fibrillation nobody wants to destabilize. The disagreement is which direct-acting antiviral regimen actually avoids trading one real risk for another.
G.T., a 66-year-old retired machinist, was found to have chronic hepatitis C on labs drawn for an unrelated pre-operative workup before a planned knee replacement — genotype 1a, likely acquired decades ago, moderate fibrosis on non-invasive staging but no cirrhosis. He's been on amiodarone for three years for persistent atrial fibrillation that failed two other antiarrhythmics before this one finally kept him in sinus rhythm, and neither he nor his cardiologist has any appetite for switching it now — his last attempt off amiodarone, years ago on a different drug, ended in a symptomatic recurrence that landed him in the emergency department. He also takes atorvastatin 40mg for hyperlipidemia, uneventfully, for the past several years.
Sofosbuvir-containing regimens carry an FDA warning specific to amiodarone: case reports describe severe, sometimes life-threatening symptomatic bradycardia when the two drugs are used together, with the mechanism not fully resolved but the association strong enough that concurrent use is now generally avoided, especially alongside a beta-blocker, which he's also on. Glecaprevir/pibrentasvir doesn't carry that specific cardiac signal, but it isn't interaction-free either — glecaprevir inhibits OATP1B1/3 and BCRP, and the labeling does not treat his statin as something to titrate around: coadministration of MAVYRET with atorvastatin, lovastatin, or simvastatin is listed as not recommended, because the exposure rise carries real myopathy and rhabdomyolysis risk. The statins the label does permit alongside it come with fixed caps rather than clinical judgment — pravastatin at half dose, rosuvastatin no higher than 10mg — so his atorvastatin 40mg has to be stopped or swapped for the course, not trimmed. Neither regimen is simply "the safe one"; each trades one interaction for a different one, and the actual decision in front of the team is which interaction has a defined answer in its own labeling without asking him to give up a drug that's kept him out of the hospital for three years. The detail that keeps resurfacing whenever his cardiologist talks about him is how specifically hard-won his current sinus rhythm was — two prior antiarrhythmics tried and abandoned before amiodarone finally worked, each attempt costing weeks of titration and monitoring — which is exactly why "just adjust the antiarrhythmic instead" isn't being treated as a serious option by anyone on his care team, cardiologist included.
Hepatology clinic, pre-treatment planning
Amiodarone stays, full stop — his last attempt off it, on a different drug years ago, put him in the emergency department with a symptomatic recurrence. I'd choose glecaprevir/pibrentasvir and hold his statin for the course. Whatever the DAA regimen, it has to work around amiodarone, not the other way around.
If his prior antiarrhythmic switch had gone smoothly instead of landing him in the ED, I'd be more open to discussing alternatives — it's specifically that real, remembered failure that makes amiodarone non-negotiable for me.
I hear that amiodarone can't move — I'd actually consider sofosbuvir/velpatasvir with intensive monitoring during the first weeks of treatment instead, and pause his atorvastatin for the course. He's tolerated the statin well, but it isn't protecting him the singular way his antiarrhythmic is. Adjusting the more replaceable drug seemed like the lower-disruption path.
I take the cardiac urgency seriously — I'm just not sure "adjust the less essential drug" and "avoid the more dangerous interaction" are actually the same recommendation once we look closely at what each interaction's own evidence looks like.
I'd go with glecaprevir/pibrentasvir, and I want to correct one thing in how we've been talking about the statin. This is not a dose-reduction interaction. The MAVYRET label puts atorvastatin in the same not-recommended bucket as lovastatin and simvastatin; the statins it does permit come with hard caps — pravastatin halved, rosuvastatin capped at 10mg. So the hepatologist's instinct to pause his atorvastatin is the labeled answer, not a concession — I'd just pause it rather than trade the whole regimen for it.
That's what actually separates the two options. The sofosbuvir-amiodarone interaction's mechanism still isn't fully understood, and its case reports describe outcomes serious enough that "monitor closely" is a meaningfully weaker safeguard than a labeled instruction. One interaction has a written disposition; the other has only closer watching for a problem that has already shown up as severe.
Agreed: glecaprevir/pibrentasvir for an 8-week course, atorvastatin held outright for the duration and resumed at his prior 40mg dose afterward — the label lists coadministration as not recommended rather than dose-adjustable — with amiodarone and metoprolol continued unchanged throughout.
Not separately argued but worth recording: the hepatologist's instinct to move the statin rather than the antiarrhythmic was adopted in full — it is what the label requires either way. What didn't hold up was the second half of that position, that moving the statin bought room to use sofosbuvir; once the two interactions were compared on whether either has a written disposition rather than on which underlying drug felt more replaceable, only one of them did.